Description:

EC0652 is a PSMA-targeted molecular imaging agent that is being developed to non-invasively identify tumors that over-express PSMA receptors.

Development Stage:

EC0652 is currently being evaluated in a Phase 0 trial for patients with advanced prostate cancer.